Use of inhaled/nebulised ipratropium bromide in addition to standard first-line treatment with inhaled/nebulised short-acting beta 2-agonist and systemic steroid in the management of acute asthma exacerbations: a systematic review and meta-analysis of randomised controlled trials.
Archives of Disease in Childhood · 2025-11-13 · Meta-analysis
Abstract
BACKGROUND: The role of inhaled/nebulised ipratropium bromide (IB) in asthma is unclear. AIMS: To assess the efficacy and safety of inhaled/nebulised IB for asthma management in children. METHODS: We searched MEDLINE, EMBASE, CINAHL, the Cochrane Central Register of Controlled Trials and the Web of Science until July 2024. We included randomised controlled trials (RCTs) and followed international guidelines for reporting systematic reviews. Outcomes included morbidity, escalation of care, length of hospital stay, mortality, adverse events and lung function. RESULTS: We included 24 studies (total participants n=3238). The hospitalisation rate (risk ratio (RR) 0.84, 95% CI 0.70 to 1.00, I² 30%), hospital stay in hours (MD 1.75, 95% CI -0.87 to 4.36, I² 15%) and paediatric intensive care (PICU) admission (RR 0.91, 95% CI 0.35 to 2.32, I² 0%) were similar. The hospitalisation rate was lower in patients who received IB nebuliser (RR 0.76, 95% CI 0.64 to 0.90, I² 0%).The asthma severity score was significantly better in the IB group (MD -0.38, 95% CI -0.63 to -0.12, I2 59%). No serious adverse events were reported. CONCLUSION: This review found high-certainty evidence that the IB nebuliser leads to a lower hospitalisation rate. However, when inhaled/nebulised IBs were analysed together, the hospitalisation rate was similar, with moderate certainty evidence. IB improved asthma clinical scores, with low certainty evidence. No difference was reported in other prespecified outcomes.Considering the current evidence and safety profile, inhaled/nebulised IB needs to be considered as an additional treatment for acute asthma exacerbation. PROSPERO REGISTRATION NUMBER: CRD42023405023.
Abstract © the authors or publisher, via PubMed. Reuse and removal
Tags
Respiratory drugs · Children · Ipratropium
Related articles
- Inhaled anticholinergics and short-acting beta(2)-agonists versus short-acting beta2-agonists alone for children with acute asthma in hospital. (Cochrane Database Syst Rev, 2014)
- Combined inhaled anticholinergics and short-acting beta2-agonists for initial treatment of acute asthma in children. (Cochrane Database Syst Rev, 2013)
- Guideline for the management of acute asthma in children: 2013 update. (S Afr Med J, 2013)
- Acute asthma in children and adolescents: should inhaled anticholinergics be added to beta(2)-agonists? (Am J Respir Med, 2003)
- The use of ipratropium bromide for the management of acute asthma exacerbation in adults and children: a systematic review. (J Asthma, 2001)
- Metered-dose inhaler ipratropium bromide in moderate acute asthma in children: A single-blinded randomised controlled trial. (J Paediatr Child Health, 2015)